PDF(Pubmed)
Abstract：
Sepsis is a complicated pathological condition in response to severe infection. It is characterized by a strong systemic inflammatory response, where multiple components of the immune system are involved. Currently, there is no treatment for sepsis. Blood platelets are known for their role in haemostasis, but they also participate in inflammation through cell-cell interaction and the secretion of inflammatory mediators. Interestingly, an increase in platelet activation, secretion, and aggregation with other immune cells (such as monocytes, T-lymphocytes and neutrophils) has been detected in septic patients. Therefore, antiplatelet therapy in terms of P2Y12 antagonists has been evaluated as a possible treatment for sepis. It was found that blocking P2Y12 receptors decreased platelet marker expression and limited attachment to immune cells in some studies, but not in others. This review addresses the role of platelets in sepsis and discusses whether antagonizing P2Y12 signalling pathways can alter the disease outcome. Challenges in studying P2Y12 antagonists in sepsis also are discussed. LINKED ARTICLES: This article is part of a themed issue on Platelet purinergic receptor and non-thrombotic disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.4/issuetoc.
摘要：
脓毒症是应对严重感染的复杂病理状况。其特征在于强烈的全身性炎症反应,并且涉及免疫系统的多个组分。目前,没有治疗败血症的方法。已知血小板在止血中的作用,但它们通过细胞-细胞相互作用和炎症介质的分泌参与炎症。有趣的是,血小板活化增加,分泌，和其他免疫细胞如单核细胞聚集，T淋巴细胞,和中性粒细胞,已在败血症患者中发现。因此,P2Y12拮抗剂方面的抗血小板治疗已被评估为脓毒症的可能治疗方法.总的来说,在某些研究中，阻断P2Y12降低了血小板标志物表达限制了对免疫细胞的附着，但不是其他人。这篇综述强调了血小板在脓毒症中的作用以及拮抗P2Y12信号通路是否可以改变预后。还将讨论在脓毒症中研究P2Y12拮抗剂的挑战。
